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Abstract
Background: Pheochromocytomas and paragangliomas (PPGLs) are rare but potentially 
harmful tumors that can vary in their clinical presentation. Tumors may be found due 
to signs and symptoms, as part of a hereditary syndrome or following an imaging 
procedure.
Objective: To investigate potential differences in clinical presentation between PPGLs 
discovered by imaging (iPPGLs), symptomatic cases (sPPGLs) and those diagnosed during 
follow-up because of earlier disease/known hereditary mutations (fPPGL).
Design: Prospective study protocol, which has enrolled patients from six European 
centers with confirmed PPGLs. Data were analyzed from 235 patients (37 iPPGLs, 36 
sPPGLs, 27% fPPGLs) and compared for tumor volume, biochemical profile, mutation 
status, presence of metastases and self-reported symptoms. iPPGL patients were 
diagnosed at a significantly higher age than fPPGLs (P < 0.001), found to have larger 
tumors (P = 0.003) and higher metanephrine and normetanephrine levels at diagnosis 
(P = 0.021). Significantly lower than in sPPGL, there was a relevant number of self-
reported symptoms in iPPGL (2.9 vs 4.3 symptoms, P < 0.001). In 16.2% of iPPGL, 
mutations in susceptibility genes were detected, although this proportion was lower 
than that in fPPGL (60.9%) and sPPGL (21.5%). Patients with PPGLs detected by 
imaging were older, have higher tumor volume and more excessive hormonal secretion 
in comparison to those found as part of a surveillance program. Presence of typical 
symptoms indicates that in a relevant proportion of those patients, the PPGL diagnosis 
had been delayed.
Précis: Pheochromocytoma/paraganglioma discovered by imaging are often symptomatic 
and carry a significant proportion of germline mutations in susceptibility genes.
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Introduction
Pheochromocytomas and paragangliomas (PPGLs) are 
neuroendocrine tumors that derive from adrenomedullary 
tissue (pheochromocytomas) in about 85% of cases and 
from extra-adrenal chromaffin tissue (paragangliomas) 
in the remainder (1). PPGLs are overall rare and occur 
with a frequency of up to 1:500 in patients with arterial 
hypertension and up to 1:1000 in unselected post 
mortem studies (2). PPGLs have the capacity to secrete 
catecholamines, which results in elevation of blood 
pressure. Thereby, the disease represents a surgically 
correctable form of hypertension. As a consequence of 
the unpredictable hormone secretion, the tumors are 
potentially very harmful if not quickly diagnosed and 
treated. In fact, retrospective analyses indicate that life-
threating events with cardiovascular complications 
including hypertensive crisis and catecholamine-
induced cardiomyopathy are not uncommon even as 
first presentation of disease (3, 4). The symptoms that 
occur in patients with PPGLs are caused by the excessive 
production of catecholamines and include headache, 
palpitations and sweating together with intermittently or 
persistently elevated blood pressure (5).
While the presence of typical signs and symptoms has 
some predictive value for the diagnosis of catecholamine 
excess, clinical presentation can vary widely with silent 
courses over a long period of time; at least 10–15% 
of cases can be completely asymptomatic and among 
patients screened due to germline mutations or because 
of imaging up to 50% or more can be normotensive and 
asymptomatic (6). With the increasing number of high-
resolution imaging procedures, a considerable proportion 
of PPGLs are now being discovered incidentally (7). As 
around 3–7% of incidentally discovered adrenal masses 
are finally diagnosed as pheochromocytoma (8, 9), current 
guidelines recommend exclusion of catecholamine excess 
in all patients with adrenal incidentalomas (2).
Over one-third of all patients with PPGLs are affected 
by germline mutations of tumor-susceptibility genes 
that considerably increase the risk to develop additional 
PPGLs at new sites and other syndrome-related neoplasms 
(2, 10). To date, at least 16 genes have been identified 
to be responsible for hereditary PPGLs (11) and exome 
sequencing approaches have defined the occurrence of 
somatic mutations in candidate genes that partly overlap 
with those found as germline variants. These advances in 
genetic and molecular diagnostics can assist in identifying 
at-risk patients and family members who might benefit 
from routine surveillance for associated syndromic 
features. Nevertheless, even for patients without these 
mutations, there is risk of recurrent disease that can 
result in cardiovascular complications or can evolve into 
metastatic progression (12).
Fortunately, once suspected, appropriate biochemical 
testing now makes it unlikely that the presence of a 
catecholamine-producing tumor will be missed. In 
particular, recognition that the O-methylated metabolites 
of catecholamines – the metanephrines – are produced 
continuously within chromaffin tumor cells with outward 
diffusion independently of variations in exocytosis, 
has led to promulgation of these analytes as superior 
for diagnosis of PPGLs compared to other analytes 
(13, 14). Consequently, Endocrine Society clinical 
practice guidelines now mandate with a strong level 
of evidence measurements of plasma free or urine 
fractionated metanephrines as first-line tests for diagnosis 
of the tumors (2). Based on these recommendations 
and the pathophysiological background of the disease, 
the indication to screen for PPGLs includes presence of 
typical signs and symptoms of catecholamine excess, 
incidental findings of suspicious adrenal or extra-adrenal 
lesions based on imaging, follow-up of an earlier history 
of PPGL or of carriers of a susceptibility gene.
Follow-up with routine periodic biochemical 
screening for PPGLs in patients at risk for the tumors has 
been consistently advocated by experts in the field (2, 15). 
The advances in imaging techniques, the much-improved 
insights into the pathophysiology and genetics of the 
disease and the high sensitivity of modern hormone 
screening approaches have considerably changed the 
composition of PPGL patients in clinical practice. Indeed, 
over the years, the proportion of patients has shifted from 
symptomatic cases to those that are incidentally detected 
or undergo routine surveillance. Despite these well-
appreciated changes, there were no prospective studies to 
compare PPGLs diagnosed by imaging or by the presence 
of typical symptoms. To fill these gaps, we have used the 
Prospective Monoamine-producing Tumor study (PMT 
study) that has included a large number of patients with 
suspected PPGL for clinical and biochemical evaluation 
(16, 17, 18, 19, 20).
Materials and methods
Patients
Patients were recruited from a total of 2056 subjects 
screened for PPGLs in a prospective multicenter study 
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0318
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 12/02/2019 12:50:16PM
via free access
N Rogowski-Lehmann et al. Pheochromocytoma discovered 
by imaging
11707:11
(Prospective Monoamine-producing Tumor study) since 
2010 according to a protocol and standard-operating 
procedures available online (https://pmt-study.pressor.
org). Out of the 2056 screened subjects, a total of 236 
patients (11.5%) were diagnosed with an abdominal 
and/or thoracic PPGL. One patient was excluded from 
the current analysis because of insufficient data. Patients 
were enrolled at six tertiary medical centers (University 
Hospital Carl Gustav Carus Dresden; University Medical 
Centre Schleswig-Holstein Lübeck; University Hospital 
of Munich; and University Hospital of Würzburg, all in 
Germany; Radboud University Medical Centre, Nijmegen, 
the Netherlands and the Institute of Cardiology, 
Warsaw, Poland) usually upon referral from primary and 
secondary care centers and according to several criteria 
establishing suspicion or risk for PPGLs: (1) signs and 
symptoms of catecholamine excess; (2) incidental finding 
by imaging; (3) known hereditary risk and (4) previous 
history of PPGL. The study protocol was approved by 
the local ethic committees of all participating centers 
(e.g. ‘Ethikkommission an der Technischen Universität 
Dresden’, ‘Ethikkommission bei der Medizinischen 
Fakultät der LMU München’, ‘Ethikkommission bei 
der Medizinischen Fakultät der Universität Würzburg’, 
‘Ethikkommission der Universität zu Lübeck’) and all 
subjects provided written informed consent prior study 
inclusion. Enrolled subjects underwent biochemical and 
imaging testing as defined in the study protocol (21) and 
in accordance to more recently published international 
guidelines (2).
While biochemical testing was done in a centralized 
lab in Dresden, Germany (21), imaging was performed 
at the discretion of the individual centers, which 
was reported to involve CTs (n = 75), MRI (n = 27) and 
functional imaging (n = 65) based on the indication and 
availability of the technique.
Patients with PPGLs confined to the head and neck 
were excluded. Patients with confirmed abdominal 
and/or thoracic PPGL were categorized according to the 
documented reason for screening: PPGLs discovered 
by imaging (iPPGLs) and symptomatic cases (sPPGLs) 
and those diagnosed as part of regularly scheduled 
follow-up because of earlier history of PPGL or known 
hereditary mutation (fPPGLs). Detection by imaging 
was defined when imaging had been performed for 
unrelated conditions without the intention to diagnose 
a PPGL. Basic clinical data were collected and spherical 
tumor volumes were calculated. All three diameters in 
tumor volumes were recorded in 167/235 (=71.1%), two 
diameters in 22/235 (=9.4%) and only one diameter in 
28/235 (=11.9%) patients. Eighteen patients (7.7%) with 
extensive metastatic disease were excluded from the 
analysis of tumor volume. Spherical tumor volume was 
calculated as a volume of an ellipsoid (V = 4/3πabc with a, 
b, and c as the provided diameters in three dimensions). 
If only two or one diameter were reported, the volume 
was calculated as a spheroid (V = 4/3πa2b) or a sphere 
(V = 4/3πa3), respectively. In case of metastatic disease, 
tumor volumes based on CT/MRI were summed, with 
the exception of cases with extensive metastatic spread. 
Only at the time of study enrollment, patients underwent 
a questionnaire as part of the study protocol that 
documented the history of a total of 12 symptoms over the 
last 30 days prior to enrollment with potential association 
to catecholamine excess. Documentation of these 
symptoms (headache, sweatiness, palpitations, pallor, 
flush, panic, constipation, nausea, chest pain, abdominal 
pain, tremor and weakness) were available from 217 out 
of 235 PPGL patients (92.3%). The number of symptoms 
present were added up to categorize patients into oligo 
symptomatic ((0–3)/12 symptoms), symptomatic 
((4–6)/12 symptoms) and highly symptomatic ((7–12)/12 
symptoms) groups.
Statistical analysis
The three groups of iPPGLs, sPPGLs and the fPPGLs were 
compared for clinical and biochemical characteristics 
including age of onset, gender, tumor size and plasma 
metanephrine levels. To compare the different groups, 
the Mann–Whitney U test and ANOVA were used and chi 
quadrat test for correlation between size and biochemical 
profile. Statistical significance was determined as a P value 
below 0.05 using the SPSS Software, version 24 (SPSS, 
Inc.). If not stated otherwise, P < 0.05 were denoted with 
one star (*) and P < 0.001 with two stars (**), respectively.
Results
Description and distribution of PPGL patient cohort
Out of the 2056 enrolled patients a total of 236 patients 
(11.5%) were diagnosed with an abdominal and/or thoracic 
PPGL. One patient was excluded because of insufficient 
data. The remaining 235 patients with confirmed disease 
had a median age of 49 years (range: 11–82) at diagnosis, 
with 57% being females and 43% males. The distribution 
for the reason to enroll the patients into the study 
protocol were 86 due to tumors discovered by imaging 
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(iPPGLs, 36.6%), 85 due to signs and symptoms indicative 
of catecholamine excess (sPPGLs, 36.2%) and 64 screened 
as part of a regular surveillance because of previous disease 
or known susceptibility gene carrier status (fPPGLs, 27.2%, 
Table 1). From the total PMT study population (n = 2056), 
inclusion criteria were available in 2055 patients. From 
those, 468 (22.8%) were included on the basis of a finding 
by imaging, and 86 (18.4%) of these patients were found 
to have a PPGL.
Clinical and genetic characteristics of PPGL patients 
detected by imaging
Age at diagnosis was significantly higher in the patients 
detected by imaging (range 17.3–82.3, median 54.7 years) 
in comparison to fPPGL patients (range 11.1–70.2, median 
39.0  years, P < 0.001) and also in sPPGL patients (range 
11–79, median 49.6 years, P = 0.015) (Fig. 1A). Overall, sex 
distribution was not different among the groups.
Tumor volume (median, range) in iPPGL patients was 
35.9 mL (0.9–904.3 mL), which was significantly larger in 
comparison to the fPPGL group (12.1 mL, 0.3–296.7 mL; 
P = 0.003, Fig. 1B) but not in comparison to those enrolled 
for symptoms (sPPGL, 34.2 mL, 2.2–2242 mL; P = 0.78). 
In 91.9% of iPPGL patients, the tumor was localized in 
one adrenal gland, while 8.1% were detected as an extra-
adrenal tumor. From the seven extra-adrenal tumors in 
the iPPGL group, six were abdominal PPGLs and one was 
a patient with hepatic metastases. In contrast, 26.6% of 
the fPPGL group was diagnosed with an extra-adrenal 
localization at first presentation.
Within the iPPGL group, five patients (5.8%) were 
diagnosed with metastatic disease at study entry (clinical 
context is provided in Table 2) and a similar proportion 
Table 1 General clinical and genetic characteristics of PPGL patients from the different screening groups.
iPPGL sPPGL fPPGL P value
Number of patients 86 85 64
Age at diagnosis (median, years) 54.7 (17.3–82.3) 49.6 (11.0–79.0) 39.0 (11.1–70.2) iPPGL vs fPPGL <0.001
sPPGL vs fPPGL <0.001
iPPGL vs sPPGL 0.015
Females, n (%) 51 (59.3) 50 (58.8) 34 (53.1) iPPGL vs fPPGL 0.45
sPPGL vs fPPGL 0.49
iPPGL vs sPPGL 0.95
Hypertension present, n (%)
 Persistent, n (%)
 Paroxysmal, n (%)
 Both, n (%)
54/81 (66.7)
37/81 (45.7)
5/81 (6.2)
12/81 (14.8)
74/80 (92.5)
30/80 (37.5)
5/80 (6.3)
39/80 (48.2)
35/58 (61.4)
25/58 (43.9)
0/58 (0)
10/58 (17.5)
iPPGL vs fPPGL 0.45
sPPGL vs fPPGL <0.001
iPPGL vs sPPGL <0.001
BMI (kg/m2) 23.9 (17.2–41.1) 24.8 (17.4–34.3) 23.4 (16.2–37.8) iPPGL vs fPPGL 0.74
sPPGL vs fPPGL 0.19
iPPGL vs sPPGL 0.28
Mutations in susceptibility genes, n (%) 12/74 (16.2) 17/79 (21.5) 39/64 (60.9) iPPGL vs fPPGL <0.001
sPPGL vs fPPGL <0.001
iPPGL vs sPPGL 0.41
 SDHA, n (%)
 SDHB, n (%)
 SDHC, n (%)
 SDHD, n (%)
 VHL, n (%)
 RET, n (%)
 NF1, n (%)
 MAX, n (%)
 HRAS, n (%)
 EPAS 1, n (%)
0/74 (0)
2/74 (2.7)
1/74 (1.4)
1/74 (1.4)
2/74 (2.7)
1/74 (1.4)
5/74 (6.8)
0/74 (0)
0/74 (0)
0/74 (0)
0/79 (0)
5/79 (6.3)
0/79 (0)
1/79 (1.3)
3/79 (3.8)
5/79 (6.3)
3/79 (3.8)
0/79 (0)
0/79 (0)
0/79 (0)
0/63 (0)
10/63 (15.9)
0/63 (0)
11/63 (17.5)
6/63 (9.5)
8/64 (12.75)
3/64 (4.7)
1/64 (1.6)
0/64 (0)
1/64 (1.6)
Malignancy at presentation, n (%) 5/84 (6.0) 5/85 (5.9) 26/65 (40.0) iPPGL vs fPPGL <0.001
sPPGL vs fPPGL <0.001
iPPGL vs sPPGL 1.0
PPGL location
 Adrenal, n (%)
 Extra-adrenal, n (%)
 Multifocal, n (%)
77/84 (91.7)
7/84 (8.3)
0/84 (0) 
76/85 (89.4)
7/85 (8.2)
2/85 (2.4) 
38/64 (59.4)
17/64 (26.6)
9/64 (14.1) 
iPPGL vs fPPGL <0.001
sPPGL vs fPPGL <0.001
iPPGL vs sPPGL 0.57 
Data are expressed as mean if not stated otherwise with range in parenthesis or frequencies.
BMI, body mass index.
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was found in symptomatic patients (5.9%), while 25 out 
of the 64 (39.1%) fPPGL patients were found to have 
metastatic disease.
Germline mutations in susceptibility genes were 
present in the majority of the patients of the fPPGL group 
(60.9%). In comparison to the fPPGL group, although 
at an overall lower proportion, a relevant number of 
patients also in the iPPGL group (16.2%; P < 0.001, clinical 
details are provided in Table 2) and in the symptomatic 
group (21.5%, P < 0.001) were found to have mutations in 
susceptibility genes.
The prospective evaluation of family history in 
the imaging group revealed no family history in 77/86 
(89.5%) while in the remaining 9 (10.5%) some evidence 
of genetic disease was apparent (six patients with 
syndromic clinical features and three patients with first 
or second-degree relatives with PPGLs). In none of these 
cases, imaging was performed for those specific reasons 
(for details see Table 2). All five of the NF1 patients had 
syndromic clinical features and one of the patients with 
SDHB mutation had a history of clear cell renal carcinoma 
so first suspicion had been a VHL mutation. In the majority 
of cases, genetic testing was done only after enrollment in 
the study protocol.
Catecholamine biochemical profile in imaging-based 
PPGL patients
For plasma metanephrine levels (median, range), no 
significant difference was detectable between iPPGL (150, 
7.0–3089 pg/mL) and sPPGL patients (259, 7–3000 pg/mL, 
P = 0.12), while they were significantly lower in the fPPGL 
group (38, 5–6888 pg/mL, P < 0.001, Fig.  2A). Plasma 
normetanephrine levels were also found to be significantly 
different between iPPGL (636, 45–25,444 pg/mL) 
and fPPGL patients (393, 48-23,333 pg/mL, P = 0.022). 
No difference in plasma normetanehphrine levels was 
detected between the iPPGL and the sPPGL patients 
(1045.5, 55–6340 pg/mL, P = 0.27, Fig.  2B). Regarding 
plasma methoxytyramine levels, no significant difference 
was evident between the three groups (median 13.75 pg/mL 
in iPPGL, 17.0 pg/mL in sPPGL (P = 0.26) and 12.5 pg/mL 
in fPPGL (P = 0.97), Fig. 2C).
Signs and symptoms in patients with PPGLs 
detected by imaging
The proportion of patients with hypertension was higher 
in the symptomatic group (92.5%) in comparison to the 
iPPGL (66.7% P < 0.001) and fPPGL (61.4%, P < 0.001), 
while the rate of persistent and paroxysmal hypertension 
was similar among the groups.
Overall, the number of self-reported symptoms was 
significantly lower in iPPGL patients (2.90, 0–11) in 
comparison to sPPGL patients (4.34, 0–10, P < 0.001), 
while it was similar in comparison to fPPGL patients 
(2.32, 0–10, P = 0.366). Accordingly, in the sPPGL group, 
the proportion of patients was shifted toward the more 
symptomatic categories (oligosymptomatic 36.8%, 
symptomatic 39.5% and highly symptomatic 23.7%) 
in comparison to the iPPGL group (oligosymptomatic 
65.4%, symptomatic 23.5% and highly symptomatic 
11.1%, Fig. 3A).
Among these symptom-based categories, lowest 
plasma normetanephrine levels were observed in 
Figure 1
Age of diagnosis (A) and tumor volume (B) in the different PPGL patient 
groups.
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oligosymptomatic patients (median 520, 48–25,444 pg/mL), 
but significantly higher levels were found in symptomatic 
(832, 70–7175 pg/mL, P = 0.009), and highly symptomatic 
patients (1410, 45–23,333 pg/mL, P = 0.018, Fig.  3C). 
A significant difference was also evident in plasma 
metanephrine levels between the oligosymptomatic 
(82, 7–3089 pg/mL), symptomatic (172.5, P < 0.001) 
and highly symptomatic groups (268, 10–6888 pg/mL, 
P < 0.001). No such difference was present for 
methoxytyramine levels.
Discussion
Herein, we have made use of a multicenter prospective 
clinical protocol that was set up to include patients 
at-risk for PPGLs. Based on these data, we demonstrate 
that patients with PPGLs detected by imaging have 
significant larger tumor volumes, are older and have 
higher metanephrine and normetanephrine levels in 
comparison to those of the regular surveillance group. 
Both improved sensitivity and overall increasing use 
Table 2 Overview on patients with PPGL diagnosed by imaging and concomitant syndromic presentation, positive family history 
or metastatic disease.
# Clinical context Reason for inclusion as putatively incidental
1 Family history or 
syndromic 
presentation
First-degree relative with PPGL, hospitalization for uncontrolled diabetes mellitus type 2 (HbA1c 
10%); routine abdominal ultrasound followed by CT scan revealed pheochromocytoma
2 Family history or 
syndromic 
presentation
Hospitalization for insufficiently controlled diabetes mellitus type 2. Indication for abdominal 
sonography because of weight loss of 7 kg. Thereby, incidental finding of an adrenal mass of 6 cm. 
Following study entry, family history reveals one daughter and one granddaughter ‘with a benign 
adrenal tumor’
3 Family history or 
syndromic 
presentation
Positive family history was only revealed after surgery and genetic diagnosis (of a SDHD mutation) as 
the patient had no contact to other family members
4 Family history or 
syndromic 
presentation
Neurofibromatosis was first diagnosed in 1998; arterial hypertension was first described in 2004. 
Right sided adrenal PPGL was detected incidentally in 2012 through imaging for abdominal pain
5 Family history or 
syndromic 
presentation
Patient was referred to a nephrologist due to elevated creatinine levels in 10/2013, which led to 
sonographic detection of a clear cell carcinoma of the right kidney. During a follow-up in 08/2015, 
an adrenal mass on the right side was detected by ultrasound. Patient came to the outpatient clinic 
with suspicion of an adrenocortical adenoma
6 Family history or 
syndromic 
presentation
Discovery of an adrenal tumor after abdominal imaging for unrelated reason; VHL was diagnosed 
clinically and genetically only after patient had undergone surgery
7 Family history or 
syndromic 
presentation
Patient had known NF1 first diagnosed in 1964. Arterial hypertension had been first diagnosed in 
1996. In 2015, the patient was seen by her general practitioner for ‘kidney pain’, which revealed a 
mass in the right retroperitoneal space. The patient was free of typical symptoms other than 
arterial hypertension, which had been known for many years
8 Family history or 
syndromic 
presentation
Abdominal ultrasound, which revealed bilateral adrenal tumors was performed due to abdominal 
pain. Only further clinical evaluation (with detection of neurofibroma) in the study center made 
the connection with the presence of neurofibromatosis
9 Family history or 
syndromic 
presentation
Diagnostic imaging performed for unexplained weight loss and increasingly difficult to maintain 
blood glucose levels with known diabetes type 1 revealed a tumor in left adrenal. Genetic testing 
was performed following surgery of the pheochromocytoma, which found a mutation for SDHC
10 Metastatic disease Prolonged respiratory infection with weight loss of 7 kg, abdominal CT scan revealed mediastinal 
lymph nodes, CT guided fine needle biopsy resulted in the diagnosis of paraganglioma which was 
found to be metastasized in the liver and the bone
11 Metastatic disease Patient was referred as an inpatient in sepsis which led to the diagnosis of endocarditis and further 
imaging revealed metastasized PGL
12 Metastatic disease Urinary retention let to the diagnosis of an adrenal tumor (with the initial suspicion of 
adrenocortical carcinoma) with the final diagnosis of metastatic PGL
13 Metastatic disease Abdominal CT scan was performed due to unspecific abdominal pain, which revealed a 
pheochromocytoma. Metastases were detected only 6 months after primary surgery
14 Metastatic disease Patient was referred because his primary care physician had made an abdominal ultrasound because 
of a suspected kidney stone. Unexpectedly, a large adrenal mass on the right side was found. 
Retrospectively, the patient for many years had signs of excessive sweating and hypertension but 
these issues became apparent only when referred to the study center, where metastatic disease was 
diagnosed
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of imaging procedures has contributed to the rise of 
incidentally detected lesions within the adrenal gland 
and elsewhere. The surprising and unexpected finding of 
this study is that a substantial proportion of patients in 
whom a PPGL was discovered by imaging for any other 
reason appeared to have clear clues of a PPGL (signs and 
symptoms or genetic cause) that should have prompted 
the search for a PPGL at an earlier stage. Furthermore, 
patients of the imaging group carried a relevant burden of 
comorbidities with a potential connection to their PPGL 
diagnosis – seven patients of the iPPGL group (8.1%) had 
major cardiovascular events.
Figure 2
Plasma metanephrine (A), normetanephrine (B) and methoxytyramine 
levels (C) at time of study inclusion in the different PPGL groups.
Figure 3
Distribution of symptomatic patients (highly symptomatic, symptomatic, 
oligo symptomatic) among the different PPGL groups (A) and median 
plasma metanephrine (B) and normetanephrine levels (C) in relation to 
the symptom score.
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The finding of higher age at presentation in 
patients with PPGLs detected by imaging is in line with 
retrospective data from the literature (7). As patients at 
higher age have a higher probability to be subjected to 
imaging techniques at older ages, the risk of detecting 
an incidental adrenal lesion also increases with age. This 
might have induced a selection bias toward a higher age 
in the PPGLs detected by imaging in the presented cohort. 
Of note, in direct comparison to symptomatic patients, the 
differences compared to those discovered by imaging were 
not striking. Similarly, there was no relevant difference 
between symptomatic and imaging-based patients in 
the localization of the tumors or proportion of apparent 
malignant disease at the time of first diagnosis. On the 
basis of these parameters, it appears that detection of a 
PPGL by imaging or based on typical clinical symptoms 
does not result in patient populations with clearly distinct 
characteristics that relate to age distribution or imaging 
results.
In the current study, overall around 12% of PPGLs 
detected by imaging were associated with highly 
suggestive symptoms; in addition, some patients had 
syndromic clinical features and some a positive family 
history (examples are provided in Table  2). Therefore, 
careful clinical examination and acquisition of medical 
histories might well have led to earlier diagnosis in a subset 
of patients in whom diagnosis was based on imaging 
findings. While the increase in imaging procedures and 
the high proportion of PPGLs based on imaging might be 
coincidental, it is intriguing to speculate that our findings 
might reflect a shift from symptom- and clinical oriented 
to imaging-based diagnostic procedures. The considerable 
rate of familial cases among those PPGLs discovered by 
imaging further suggests that in some instances regular 
follow-up and/or genetic counseling had not been 
appropriately followed.
As to be expected from the inclusion criteria, patients 
from the symptomatic group had an increased likelihood 
of a high symptom score, which was paralleled by higher 
levels of plasma metanephrines and normetanephrines. 
Of note, within the imaging group, 21.5% of patients 
presented with paroxysmal hypertension either isolated 
or in combination with persistent hypertension. Similarly, 
within the last month prior study enrollment, a relevant 
number of these patients reported on at least four of the 
pre-defined symptoms that had been associated with 
catecholamine excess (headache, sweatiness, palpitations, 
pallor, flush, panic, constipation, nausea, chest pain, 
abdominal pain, tremor and weakness). In a recent 
meta-analysis on the – often retrospective – literature of 
PPGL-related signs and symptoms, no single clinical feature 
could be identified with a particular value in diagnosing or 
excluding PPGLs (22). However, while prospective studies 
involving comparisons to patients in whom PPGL had 
been excluded will be required, it seems prudent that a 
high symptomatic burden should raise clinical suspicion 
for the presence of catecholamine excess. Obviously, this 
information has to be gathered by clinical examination 
and by taking a detailed patient history.
Given the strong genetic contributions for the 
development of PPGLs and the lack of a reliable marker 
for the distinction between benign and malignant disease, 
follow-up with routine periodic biochemical screening for 
PPGLs in patients at risk has been consistently advocated 
by experts (2, 15). However, there remains a wide gap 
between what is recommended and what is followed 
in routine clinical practice. Specifically, patients with 
NF1 mutations were recommended until very recently, 
to undergo screening for PPGLs only when additional 
symptoms raised the suspicion of catecholamine excess. 
A recent study by Moramarco and colleagues reported on 
a relevant proportion of PPGL cases detected incidentally 
in patients with NF1 (23). These findings, which are inline 
with our own and other recent findings support need for 
change to recommendations for NF1 patients such that 
all should receive some form of periodic surveillance for 
PPGLs irrespective of other clinical clues.
As indicated in two recent reports (12, 15), this 
gap reflects the inconsistent and relative lack of data 
concerning risk of recurrent or new disease and the 
associated paucity of evidence for any improved clinical 
outcome that might be achieved by routine follow-up. 
The data presented herein provide indirect evidence for 
the effectiveness of screening procedures in the context 
of a known hereditary risk for the development of PPGLs: 
patients who underwent diagnosis in the follow-up group 
had significantly lower levels of plasma catecholamine 
metabolites with lower burden of clinical symptoms.
Within the surveillance group, the prevalence of 
malignancy was the highest, which likely reflects the large 
proportion of patients with SDHB mutations. However, 
also in the imaging group a considerably high rate of 
susceptibility gene mutations were evident. While no 
past or family history in the majority of these patients 
had been indicative for a hereditary cause, almost one 
quarter were found to be gene carriers. As these findings 
clearly impact on the follow-up of the index patient and 
on genetic risk of first-grade family members, also PPGL 
patients detected on the basis of imaging should be 
offered genetic counseling on a regular basis.
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The strength of the current study is the substantial 
sample size of PPGL patients that have prospectively 
undergone follow-up. We acknowledge the imperfect 
data coverage, differences in imaging protocols among 
centers and yet limited duration of the observation 
period. Despite these limitations, we demonstrate that 
also patients with PPGLs discovered by imaging carry a 
considerable morbidity risk that should be matched by 
appropriate and specialized medical care. Notably, in a 
subgroup of patients despite their apparently incidental 
diagnosis medical and family history and careful clinical 
examination would already have provided good reasons 
for biochemical screening independent of imaging studies.
While we can only speculate on the individual reasons 
for missed or delayed diagnosis, we believe that the most 
important measures to improve current shortcomings in 
early detection of PPGL patients comprises continuous 
medical education of general physicians and medical 
disciplines (e.g. general internal medicine, cardiology, 
nephrology) who have a likelihood to encounter a PPGL 
patient. Secondly, active invitation of patients with a 
PPGL history or hereditary background into specific 
surveillance programs could likely increase adherence to 
follow-up studies. Finally, privacy law regulations in place 
in some European countries have to be balanced against 
the risk to lose access to information that is relevant for 
clinical decision making.
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